Trials / Completed
CompletedNCT00240318
A Study To Evaluate the Effect of Rosuvastatin On Intravascular Ultrasound-Derived Coronary Atheroma Burden (ASTEROID)
A 104-Week, Open-label, Multi-centre, Phase IIIb Study Evaluating the Effect of Treatment With Rosuvastatin 40 mg on Atherosclerotic Disease as Measured by Intravascular Ultrasound and Quantitative Coronary Angiography in Subjects Undergoing Coronary Angiography Who Have Coronary Artery Disease
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 450 (planned)
- Sponsor
- AstraZeneca · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to see if 40 mg of rosuvastatin taken daily will reduce the atherosclerosis (fatty deposits) in your arteries
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Rosuvastatin calcium |
Timeline
- Start date
- 2002-11-01
- Primary completion
- 2005-11-01
- Completion
- 2005-11-01
- First posted
- 2005-10-18
- Last updated
- 2010-11-19
Locations
61 sites across 8 countries: United States, Australia, Belgium, Canada, France, Italy, Netherlands, Spain
Source: ClinicalTrials.gov record NCT00240318. Inclusion in this directory is not an endorsement.